Table 2 The relationship between m6A enzyme mRNA expression and clinicopathological parameters with clinical patients of breast cancer

Age

≤51 (16)

0.89 ± 0.54

0.80 ± 0.53

0.80 ± 0.44

2.14 ± 1.31

0.92 ± 1.71

1.59 ± 1.23

> 51 (20)

0.72 ± 0.50

0.81 ± 0.56

0.79 ± 0.36

1.85 ± 1.24

0.76 ± 0.46

1.78 ± 1.38

ER (IHC)

- (13)

0.55 ± 0.18

0.53 ± 0.30

0.81 ± 0.41

1.44 ± 1.39

0.59 ± 0.63

1.07 ± 0.50

+(23)

0.89 ± 0.59*

0.93 ± 0.59*

0.78 ± 0.38

2.21 ± 1.12

0.92 ± 0.49*

2.02 ± 1.48*

PR (IHC)

-(15)

0.59 ± 0.23

0.65 ± 0.36

0.78 ± 0.44

1.33 ± 0.90

0.63 ± 0.46

1.08 ± 0.23

+(21)

0.95 ± 0.63*

0.96 ± 0.64*

0.81 ± 0.35

2.33 ± 1.07*

1.01 ± 0.58*

2.20 ± 1.52*

HER2 (IHC)

-(14)

0.72 ± 0.38

0.81 ± 0.45

0.77 ± 0.36

2.46 ± 1.32

0.74 ± 0.41

1.48 ± 0.71

+(22)

0.81 ± 0.58

0.81 ± 0.59

0.80 ± 0.40

1.67 ± 1.11

0.86 ± 0.62

1.83 ± 1.55

TNBC

+(4)

0.31 ± 0.07

0.30 ± 0.21

0.60 ± 0.09

0.89 ± 0.36

0.41 ± 0.33

1.13 ± 0.68

-(32)

0.83 ± 0.51*

0.96 ± 0.54

0.81 ± 0.40

2.08 ± 1.26

0.86 ± 0.56

1.77 ± 1.36